A second confirmatory, randomized, withdrawal study of INOpulse in patients with Pulmonary Arterial Hypertension (PAH).
Phase of Trial: Phase III
Latest Information Update: 07 Aug 2017
At a glance
- Drugs Nitric acid (Primary)
- Indications Pulmonary arterial hypertension
- Focus Registrational; Therapeutic Use
- Acronyms INOvation-RW
- 07 Aug 2017 According to a Bellerophon Therapeutics media release, the company plans to initiate this study in 2018 with top line results expected in 2019.
- 09 Jan 2017 New trial record
- 04 Jan 2017 According to a Bellerophon Therapeutics media release, company anticipates regulatory approval of INOpulse in 2022.